Long-term antiviral therapy, although effective for treatment of hepatitis B, might select the emergence of drug-resistant hepatitis B virus (HBV) mutants. Detection of HBV mutants and determination of viral titre are two crucial parameters for monitoring treatment response and occurrence of mutants. In this study, we take lamivudine resistance as an example to develop a method that can determine both parameters in a single-tube PCR reaction.
Methods
The method contained two consecutive steps: in the first step, real-time PCR was used for quantification; in the second step, a novel annealing curve analysis was used for detecting YMDD mutants. For accurate quantification, PCR primers and hybridization probes were chosen from highly conserved regions to ensure the equivalent amplification of all HBV genotypes. Within the sensor probe, there were signature nucleotide polymorphisms that could effectively differentiate YMDD mutants from wild type by distinct melting temperatures (Tm) values. The clinical applicability of the assay was tested in serial samples from 90 patients receiving lamivudine treatment.
Results
This assay could readily differentiate YMDD, YIDD and YVDD mutants by their distinct Tm values. The quantification results showed great consistency in a linear range from 103 to 1011 copies/ml. Moreover, this assay could detect YMDD mutants accounting for ≤10% of the total viral population. Its clinical feasibility has been verified in primary specimens.
Conclusions
The newly designed YMDD detection method is simple, sensitive, cost-effective, time-saving and provides a useful tool for follow-up of patients treated with lamivudine or other antiviral drugs.
References
1.
ChenD.S.From hepatitis to hepatoma: lessons from type B viral hepatitis.Science1993; 262: 369–370.
2.
LeeW.M.Hepatitis B virus infection.N Engl J Med1997; 337: 1733–1745.
3.
ChenP.J., ChenD.S.Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives.Semin Liver Dis1999; 19: 253–262.
4.
MalikA.H., LeeW.M.Hepatitis B therapy: the plot thickens.Hepatology1999; 30: 579–581.
5.
LingR., MutimerD., AhmedM.Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.Hepatology1996; 24: 711–713.
6.
TipplesG.A., MaM.M., FischerK.P., BainV.G., KnetemanN.M., TyrrellD.L.Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.Hepatology1996; 24: 714–717.
7.
BartholomeuszA., LocarniniS.A.Antiviral drug resistance: clinical consequences and molecular aspects.Semin Liver Dis2006; 26: 162–170.
8.
ChanyM., LiangT.J.Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.Gastroenterology2007; 132: 1574–1585.
9.
PallierC., CasteraL., SoulierA.Dynamics of hepatitis B virus resistance to lamivudine.J Virol2006; 80: 643–653.
10.
KirishimaT., OkanoueT., DaimonY.Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.J Hepatol2002; 37: 259–265.
11.
PasS.D., de ManR.A., FriesE., OsterhausA.D., NiestersH.G.The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridization.J Clin Virol2002; 25: 63–71.
12.
LiawY.F., ChienR.N., YehC.T., TsaiS.L., ChuC.M.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.Hepatology1999; 30: 567–572.
13.
LiawY F.. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Antivir Chem Chemother2001; 12: 67–71.
14.
YuenM.F., KatoT., MizokamiM.Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.J Hepatol2003; 39: 850–855.
15.
YuenM.F., YuanH.J., SablonE.Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.J Clin Microbiol2004; 42: 3932–3936.
16.
LiawY.F., ChienR.N., YehC.T.No benefit to continue lamivudine therapy after emergence of YMDD mutations.Antivir Ther2004; 9: 257–262.
17.
LiawY F.. Therapy of chronic hepatitis B: current challenges and opportunities.J Viral Hepat2002; 9: 393–399.
18.
PerrilloR., SchiffE., YoshidaE.Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.Hepatology2000; 32: 129–134.
19.
LamperticoP., ViganoM., ManentiE., IavaroneM., LunghiG., ColomboM.Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.Hepatology2005; 42: 1414–1419.
20.
RivkinA.A review of entecavir in the treatment of chronic hepatitis B infection.Curr Med Res Opin2005; 21: 1845–1856.
21.
LeemansW.F., FlinkH.J., JanssenH.L., NiestersH.G., SchalmS.W., de ManR.A.The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.J Hepatol2006; 44: 507–511.
22.
KobayashiS., IdeT., SataM.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers.J Hepatol2001; 34: 584–586.
23.
LeeC.H., KimS.O., ByunK.S.Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.Gastroenterology2006; 130: 1144–1152.
24.
AllenM.I., GauthierJ., DesLauriersM.Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine.J Clin Microbiol1999; 37: 3338–3347.
25.
JardiR., ButiM., Rodriguez-FriasF.Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.J Virol Methods1999; 83: 181–187.
26.
StuyverL., Van GeytC., De GendtS.Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.J Clin Microbiol2000; 38: 702–707.
27.
AberleS.W., KletzmayrJ., WatschingerB., SchmiedB., VetterN., Puchhammer-StocklE.Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.J Clin Microbiol2001; 39: 1972–1974.
28.
WhalleyS.A., BrownD., TeoC.G., DusheikoG.M., SaundersN.A.Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler.J Clin Microbiol2001; 39: 1456–1459.
29.
WightmanF., WaltersT., AyresA.Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains.J Clin Microbiol2004; 42: 3809–3812.
30.
PuniaP., CaneP., TeoC.G., SaundersN.Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR.J Hepatol2004; 40: 986–992.
31.
CaneP.A., CookP., RatcliffeD., MutimerD., PillayD.Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus.Antimicrob Agents Chemother1999; 43: 1600–1608.
32.
BaiY.J., ZhaoJ.R., LvG.T.Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization.World J Gastroenterology2003; 9: 2344–2347.
33.
JangH., ChoM., HeoJ.Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus.J Clin Microbiol2004; 42: 4181–4188.
34.
LindstromA., OdebergJ., AlbertJ.Pyrosequencing for detection of lamivudine-resistant hepatitis B virus.J Clin Microbiol2004; 42: 4788–4795.
35.
SablonE., ShapiroF.Advances in molecular diagnosis of HBV infection and drug resistance.Int J Med Sci2005; 2: 8–16.
36.
CarmanW., ThomasH., DomingoE.Viral genetic variation: hepatitis B virus as a clinical example.Lancet1993; 341: 349–353.
37.
StuyverL., De GendtS., Van GeytC.A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.J Gen Virol2000; 81: 67–74.
38.
NorderH., CourouceA-M, MagniusL.O.Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes.Virology1994; 198: 489–503.
39.
KaoJ.H., ChenP.J., LaiM.Y., ChenD.S.Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.Gastroenterology2000; 118: 554–559.
40.
YehS.H., TsaiC.Y., KaoJ.H.Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis.J Hepatol2004; 41: 659–666.
